Lawrence Erik Kurzius Acquires 40,000 Shares of Elanco Animal Health (NYSE:ELAN) Stock

Posted by Stanley Muller on Aug 23rd, 2026

Elanco Animal Health Incorporated (NYSE:ELAN – Get Free Report) Director Lawrence Erik Kurzius purchased 40,000 shares of Elanco Animal Health stock in a transaction that occurred on Thursday, August 20th. The shares were bought at an average cost of $23.40 per share, for a total transaction of $936,000.00. Following the transaction, the director directly owned 188,647 shares of the company’s stock, valued at $4,414,339.80. This represents a 26.91% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Elanco Animal Health Price Performance

Shares of NYSE ELAN opened at $24.05 on Friday. The stock has a market capitalization of $12.02 billion, a PE ratio of -58.66, a P/E/G ratio of 1.44 and a beta of 1.67. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10. The business has a fifty day moving average price of $24.56 and a two-hundred day moving average price of $24.01. Elanco Animal Health Incorporated has a fifty-two week low of $17.11 and a fifty-two week high of $27.98.

Elanco Animal Health (NYSE:ELAN – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The firm had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.31 billion. During the same period in the prior year, the company posted $0.26 EPS. The company’s revenue was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, equities analysts predict that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in shares of Elanco Animal Health in the 2nd quarter valued at approximately $1,202,198,000. Primecap Management Co. CA acquired a new position in Elanco Animal Health during the 2nd quarter worth approximately $1,118,402,000. The Manufacturers Life Insurance Company acquired a new position in Elanco Animal Health during the 2nd quarter worth approximately $205,636,000. UBS Group AG lifted its stake in Elanco Animal Health by 56.7% in the 3rd quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock valued at $331,669,000 after purchasing an additional 5,961,457 shares during the last quarter. Finally, Sei Investments Co. lifted its stake in Elanco Animal Health by 737.5% in the 1st quarter. Sei Investments Co. now owns 5,650,393 shares of the company’s stock valued at $135,214,000 after purchasing an additional 4,975,721 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on ELAN shares. KeyCorp raised their target price on shares of Elanco Animal Health from $29.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Morgan Stanley upped their price target on shares of Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 22nd. Citigroup increased their price target on shares of Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Wall Street Zen cut shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $29.09.

Get Our Latest Stock Report on Elanco Animal Health

Elanco Animal Health Company Profile

(Get Free Report)

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.